Aurion Biotech, Inc. — Form D
Aurion Biotech, Inc. of SEATTLE, WA, a company, filed a Form D exempt-offering notice with the SEC on 2022-04-21. The offering totals $120.3M, of which $55.3M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-04-21
- Form: D
- Accession: 0001924356-22-000002
- Industry: Biotechnology
- Exemptions: 06c
- Total offering: $120.3M
- Amount sold: $55.3M
- Remaining: $65.0M
- Investors: 9
- Date of first sale: 2022-04-05
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-442906
Issuer
- Name: Aurion Biotech, Inc.
- CIK: 0001924356
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 117 E. LOUISA STREET, SEATTLE, WA, 98102
- Phone: 206-701-5840
Officers, directors & promoters (10)
| Name | Role | Location |
|---|
| Andrew ElBardissi | Director | St. Louis Park, MN |
| Tom Frinzi | Director | Aliso Viejo, CA |
| Patrick Lally | Director | Seattle, WA |
| JEANNETTE BANKES | Director | SEATTLE, WA |
| LINK WILLIAM | Director | SEATTLE, WA |
| GREG KUNST | Director | SEATTLE, WA |
| GREG KUNST | Executive Officer | SEATTLE, WA |
| ARNAUD LACOSTE | Executive Officer | SEATTLE, WA |
| CHRISTINE MCCAULEY | Director | SEATTLE, WA |
| DAVID ROSTOV | Executive Officer | SEATTLE, WA |
Other filings by this issuer (2)
More